Cipla signs agreement with Merck for Molnupiravir

Molnupiravir is an investigational oral antiviral drug currently being studied in a Phase 3 trial for the treatment of non-hospitalized patients with confirmed COVID-19

Merck publishes sustainability report for 2020

The company is pursuing specific goals in the areas of science and technology, value chain as well as climate and the environment.

Merck accelerates expansion plans for single-use products critical to manufacturing vaccines

The company will add a single-use assembly production unit at its Life Science Center in Molsheim, France.

Merck brings new renewable energy to the grid through VPPA with Enel Green Power

Has signed a 12-year, off-site, virtual power purchase agreement (VPPA) with Enel Green Power

Merck FY20 sales up 8.6% euro 17.5 bn

Merck forecasts organic growth of EBITDA pre in a high single-digit to low teens percentage range in 2021.

Kelun-Biotech’s Sac-TMT shows breakthrough results in first-line lung cancer trial

Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors

FDA approves combo therapy for Cisplatin-ineligible muscle-invasive bladder cancer patients

The approvals target adult MIBC patients who are ineligible for cisplatin-based chemotherapy

FDA approves Promega’s OncoMate test to guide personalised treatment for endometrial cancer

OncoMate MSI Dx Analysis System is a PCR-based assay designed to evaluate MSI status in tumor tissue

MSD secures $700 million boost from Blackstone to advance broad-cancer ADC therapy Sac-TMT

Lilly, Novo Nordisk closer to deal with Trump administration to slash obesity drug prices to $149/month

The discussions come as part of the administration’s broader efforts to drive down drug prices and increase patient access to essential therapies